NASDAQ:STAA - STAAR Surgical Stock Price, Forecast & News

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) released its quarterly earnings data on Wednesday, February, 26th. The medical instruments supplier reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.09. The medical instruments supplier earned $38.88 million during the quarter, compared to analyst estimates of $39.10 million. STAAR Surgical had a return on equity of 13.84% and a net margin of 6.15%. During the same period last year, the company posted $0.02 EPS. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for STAAR Surgical.

STAAR Surgical issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $177.2-177.2 million, compared to the consensus revenue estimate of $177.48 million.

3 Wall Street analysts have issued 12 month price targets for STAAR Surgical's stock. Their forecasts range from $45.00 to $56.00. On average, they expect STAAR Surgical's stock price to reach $49.00 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Price Targets for STAAR Surgical.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

News coverage about STAA stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. STAAR Surgical earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for STAAR Surgical.

STAAR Surgical saw a drop in short interest in February. As of February 14th, there was short interest totalling 3,700,000 shares, a drop of 12.9% from the January 30th total of 4,250,000 shares. Based on an average daily trading volume, of 367,700 shares, the short-interest ratio is currently 10.1 days. Currently, 8.4% of the company's shares are short sold. View STAAR Surgical's Current Options Chain.

Some companies that are related to STAAR Surgical include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include NVIDIA (NVDA), Rockwell Medical (RMTI), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Vanda Pharmaceuticals (VNDA), Agile Therapeutics (AGRX), Amarin (AMRN), Immunomedics (IMMU), Karyopharm Therapeutics (KPTI) and TG Therapeutics (TGTX).

STAAR Surgical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (8.48%), Baillie Gifford & Co. (4.36%), Capital International Investors (4.12%), State Street Corp (2.56%), Janus Henderson Group PLC (1.98%) and Defender Capital LLC. (1.35%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten, Scott D Barnes and William P Wall. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Barclays PLC, Palo Alto Investors LP, State Street Corp, BosValen Asset Management Ltd, Principal Financial Group Inc., King Luther Capital Management Corp and Chicago Equity Partners LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten and Scott D Barnes. View Insider Buying and Selling for STAAR Surgical.

STAA stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Broadfin Capital LLC, Loomis Sayles & Co. L P, UBS Asset Management Americas Inc., Janus Henderson Group PLC, Royce & Associates LP, Bank of America Corp DE and Driehaus Capital Management LLC. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $31.03.

STAAR Surgical has a market capitalization of $1.38 billion and generates $123.95 million in revenue each year. The medical instruments supplier earns $4.97 million in net income (profit) each year or $0.28 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.View Additional Information About STAAR Surgical.

The official website for STAAR Surgical is http://www.staar.com/.

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]